Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Predicting the presence of oral squamous cell carcinoma using commonly dysregulated microRNA in oral swirls.

Yap T, Koo K, Cheng L, Vella LJ, Hill AF, Reynolds EC, Nastri AL, Cirillo N, Seers CA, McCullough M.

Cancer Prev Res (Phila). 2018 May 15. pii: canprevres.0409.2017. doi: 10.1158/1940-6207.CAPR-17-0409. [Epub ahead of print]

PMID:
29764807
2.

Reporting on longitudinal live birth rates and cumulative delivery rates are more realistic outcome measures than sperm retrieval rates in couples undergoing mTESE-ICSI.

Almekaty K, Abomelha S, Thum Y, Nicopoullos J, Bracewell-Milnes T, Yap T, Minhas S.

Hum Fertil (Camb). 2018 May 10:1-6. doi: 10.1080/14647273.2018.1472396. [Epub ahead of print]

PMID:
29745280
3.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
4.

Annexins in Glaucoma.

Yap TE, Davis BM, Guo L, Normando EM, Cordeiro MF.

Int J Mol Sci. 2018 Apr 17;19(4). pii: E1218. doi: 10.3390/ijms19041218. Review.

5.

Fertility preservation in testicular cancer - predictors of spermatogenesis.

Moody JA, Ahmed K, Horsfield C, Pedersen MRV, Yap T, Shabbir M.

BJU Int. 2018 Apr 17. doi: 10.1111/bju.14214. [Epub ahead of print]

PMID:
29667332
6.

Introduced bullfrog facilitates pathogen invasion in the western United States.

Yap TA, Koo MS, Ambrose RF, Vredenburg VT.

PLoS One. 2018 Apr 16;13(4):e0188384. doi: 10.1371/journal.pone.0188384. eCollection 2018.

7.

A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer.

Sri D, Sujenthiran A, Lam W, Minter J, Tinwell BE, Corbishley CM, Yap T, Sharma DM, Ayres BE, Watkin NW.

BJU Int. 2018 Mar 31. doi: 10.1111/bju.14222. [Epub ahead of print]

PMID:
29604228
8.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

PMID:
29533782
9.

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F.

Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Review.

PMID:
29508857
10.

TEAM-UP for quality: a cluster randomized controlled trial protocol focused on preventing pressure ulcers through repositioning frequency and precipitating factors.

Yap TL, Kennerly SM, Horn SD, Bergstrom N, Datta S, Colon-Emeric C.

BMC Geriatr. 2018 Feb 20;18(1):54. doi: 10.1186/s12877-018-0744-0.

11.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2018 Feb 2. doi: 10.1158/1078-0432.CCR-17-2494. [Epub ahead of print] Review.

PMID:
29420224
12.

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-Edged Sword.

Tang C, Jiang W, Yap TA.

JAMA Oncol. 2018 Jan 11. doi: 10.1001/jamaoncol.2017.4606. [Epub ahead of print] No abstract available.

PMID:
29327039
13.

A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.

Faure Walker NA, Norris JM, Shah TT, Yap T, Cathcart P, Moore CM, Ahmed HU, Emberton M, Minhas S.

Urol Oncol. 2018 Feb;36(2):67-76. doi: 10.1016/j.urolonc.2017.12.002. Epub 2017 Dec 23. Review.

PMID:
29277585
14.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

15.

Precision oncology: East meets West.

Subbiah V, Rodon J, Yap TA.

Int J Cancer. 2018 May 1;142(9):1734-1737. doi: 10.1002/ijc.31218. Epub 2018 Jan 4. No abstract available.

PMID:
29243227
16.

Precision Medicine: Progress, Pitfalls, and Promises.

Pilié PG, LoRusso PM, Yap TA.

Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. No abstract available.

PMID:
29203693
17.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
18.

Resident Vignettes for Assessing Care Quality in Nursing Homes.

Colón-Emeric CS, Corazzini KN, McConnell ES, Pan W, Toles MP, Hall R, Batchelor-Murphy M, Yap TL, Anderson AL, Burd A, Amarasekara S, Anderson RA.

J Am Med Dir Assoc. 2018 May;19(5):405-410. doi: 10.1016/j.jamda.2017.10.018. Epub 2017 Nov 22.

PMID:
29174560
19.

Batrachochytrium salamandrivorans and the Risk of a Second Amphibian Pandemic.

Yap TA, Nguyen NT, Serr M, Shepack A, Vredenburg VT.

Ecohealth. 2017 Dec;14(4):851-864. doi: 10.1007/s10393-017-1278-1. Epub 2017 Nov 16. Review.

PMID:
29147975
20.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

PMID:
29093017
21.

Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach.

Cheow ESH, Cheng WC, Yap T, Dutta B, Lee CN, Kleijn DPV, Sorokin V, Sze SK.

J Proteome Res. 2018 Jan 5;17(1):499-515. doi: 10.1021/acs.jproteome.7b00651. Epub 2017 Nov 7.

PMID:
29068691
22.

Development of Molecularly Driven Targeted Combination Strategies.

Yap TA, Rodon J.

Oncologist. 2017 Dec;22(12):1421-1423. doi: 10.1634/theoncologist.2017-0402. Epub 2017 Oct 16. No abstract available.

23.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

24.

Effect of Promoting High-Quality Staff Interactions on Fall Prevention in Nursing Homes: A Cluster-Randomized Trial.

Colón-Emeric CS, Corazzini K, McConnell ES, Pan W, Toles M, Hall R, Cary MP Jr, Batchelor-Murphy M, Yap T, Anderson AL, Burd A, Amarasekara S, Anderson RA.

JAMA Intern Med. 2017 Nov 1;177(11):1634-1641. doi: 10.1001/jamainternmed.2017.5073.

PMID:
28973516
25.

Neuronal defects an etiological factor in congenital pelviureteric junction obstruction?

How GY, Chang KTE, Jacobsen AS, Yap TL, Ong CCP, Low Y, Allen JC, Kuick CH, Lim MZL, Laksmi NK.

J Pediatr Urol. 2018 Feb;14(1):51.e1-51.e7. doi: 10.1016/j.jpurol.2017.07.014. Epub 2017 Sep 1.

PMID:
28927720
26.

Anorectal malformation & Hirschsprung's disease: A cross-sectional comparison of quality of life and bowel function to healthy controls.

Nah SA, Ong CCP, Saffari SE, Ong LY, Yap TL, Low Y, Jacobsen AS.

J Pediatr Surg. 2017 Aug 25. pii: S0022-3468(17)30514-6. doi: 10.1016/j.jpedsurg.2017.08.018. [Epub ahead of print]

PMID:
28916047
27.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA.

Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15.

PMID:
28838399
28.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
29.

Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia.

Rajagopal R, Abd-Ghafar S, Ganesan D, Bustam Mainudin AZ, Wong KT, Ramli N, Jawin V, Lum SH, Yap TY, Bouffet E, Qaddoumi I, Krishnan S, Ariffin H, Abdullah WA.

J Glob Oncol. 2016 Jun 15;3(2):143-156. doi: 10.1200/JGO.2015.002659. eCollection 2017 Apr.

30.

Targeting ATR in cancer medicine.

Sundar R, Brown J, Ingles Russo A, Yap TA.

Curr Probl Cancer. 2017 Jul - Aug;41(4):302-315. doi: 10.1016/j.currproblcancer.2017.05.002. Epub 2017 May 17. Review.

PMID:
28662958
31.

Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.

Ariffin H, Azanan MS, Abd Ghafar SS, Oh L, Lau KH, Thirunavakarasu T, Sedan A, Ibrahim K, Chan A, Chin TF, Liew FF, Jeyamogan S, Rosli ES, Baharudin R, Yap TY, Skinner R, Lum SH, Hainaut P.

Cancer. 2017 Nov 1;123(21):4207-4214. doi: 10.1002/cncr.30857. Epub 2017 Jun 27.

PMID:
28654149
32.

Challenges in GC-MS analysis: Case studies on phenibut and ethylphenidate.

Lee HZS, Ong MC, Lim JLW, Yap TWA.

Forensic Sci Int. 2017 Aug;277:166-178. doi: 10.1016/j.forsciint.2017.06.002. Epub 2017 Jun 9.

PMID:
28651175
33.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA.

Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.

PMID:
28576843
34.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

35.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Sundar R, Chénard-Poirier M, Collins DC, Yap TA.

Front Med (Lausanne). 2017 Apr 10;4:39. doi: 10.3389/fmed.2017.00039. eCollection 2017. Review.

36.

Global Fecal and Plasma Metabolic Dynamics Related to Helicobacter pylori Eradication.

Yap TW, Leow AH, Azmi AN, Callahan DL, Perez-Perez GI, Loke MF, Goh KL, Vadivelu J.

Front Microbiol. 2017 Mar 30;8:536. doi: 10.3389/fmicb.2017.00536. eCollection 2017.

37.

Circulating tumor DNA-From bench to bedside.

Lim JSJ, Janku F, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1.

PMID:
28416241
38.

Screening Commercial Vehicle Drivers for Obstructive Sleep Apnea: Tools, Barriers, and Recommendations.

Evans KA, Yap T, Turner B.

Workplace Health Saf. 2017 Oct;65(10):487-492. doi: 10.1177/2165079917692597. Epub 2017 Apr 17.

PMID:
28414584
39.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
40.

Precision medicine in oncology.

Takebe N, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):163-165. doi: 10.1016/j.currproblcancer.2017.01.001. Epub 2017 Jan 24. No abstract available.

PMID:
28372822
41.

Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.

Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR.

Radiology. 2017 Jul;284(1):88-99. doi: 10.1148/radiol.2017161965. Epub 2017 Mar 16.

PMID:
28301311
42.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
43.

Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie's disease: a safety profile.

Yan S, Yap T, Minhas S.

Transl Androl Urol. 2017 Feb;6(1):123-126. doi: 10.21037/tau.2016.12.08. No abstract available.

44.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
45.

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Review.

PMID:
28214087
46.

Study of Individualization and Bias in Nursing Home Fall Prevention Practices.

Colón-Emeric CS, Corazzini K, McConnell E, Pan W, Toles M, Hall R, Batchelor-Murphy M, Yap TL, Anderson AL, Burd A, Anderson RA.

J Am Geriatr Soc. 2017 Apr;65(4):815-821. doi: 10.1111/jgs.14675. Epub 2017 Feb 10.

47.

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Brown JS, O'Carrigan B, Jackson SP, Yap TA.

Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Review.

48.

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Yap TA, Popat S.

J Thorac Oncol. 2017 Jan;12(1):12-14. doi: 10.1016/j.jtho.2016.10.019. No abstract available.

49.

Emerging biomarkers for PD-1 pathway cancer therapy.

Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA.

Biomark Med. 2017 Jan;11(1):53-67. Epub 2016 Dec 12. Review.

PMID:
27936870
50.

Implementation of a Recovery-Oriented Training Program for Psychiatric Nurses in the Inpatient Setting: A Mixed-Methods Hospital Quality Improvement Study.

Repique RJ, Vernig PM, Lowe J, Thompson JA, Yap TL.

Arch Psychiatr Nurs. 2016 Dec;30(6):722-728. doi: 10.1016/j.apnu.2016.06.003. Epub 2016 Jun 23.

PMID:
27888966

Supplemental Content

Support Center